AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35927059 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus plane block combined with pectoral nerve block I before general anesthesia + PCIA
Number of subjects: 30
Study 35927059 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone + PCIA (control group)
Number of subjects: 30
Study 35927059 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus plane block combined with pectoral nerve block I + PCIA
Number of subjects: 30
Study 36341490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual advertisements
Number of subjects: 182
Study 36341490 — intervention group
Group type: COMPARATOR
Intervention: Nonsexual advertisements
Number of subjects: 182
Study 34607574 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 97
Study 34607574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 35762079 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 38
Study 35762079 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 38
Study 33833944 — intervention group
Group type: EXPERIMENTAL
Intervention: Myval THV
Number of subjects: 108
Study 33833944 — intervention group
Group type: COMPARATOR
Intervention: Sapien 3 THV
Number of subjects: 108
Study 33833944 — intervention group
Group type: COMPARATOR
Intervention: Sapien XT THV
Number of subjects: 108
Study 33833944 — intervention group
Group type: EXPERIMENTAL
Intervention: Myval THV vs Sapien XT THV
Number of subjects: 108
Study 35488509 — intervention group
Group type: EXPERIMENTAL
Intervention: PSO17 10%
Number of subjects: 12
Study 35488509 — intervention group
Group type: EXPERIMENTAL
Intervention: PSO17 20%
Number of subjects: 12
Study 35488509 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 12
Study 33293201 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT) - one guided online group session
Number of subjects: 72
Study 33293201 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 72
Study 35753072 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative high‐intensity interval training (HIIT), four times weekly (EX; n = 20)
Number of subjects: 30
Study 35753072 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative high‐intensity interval training (HIIT) (EX; n = 20)
Number of subjects: 30
Study 35753072 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CON; n = 10)
Number of subjects: 30
Study 34551471 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg IV)
Number of subjects: 90
Study 34551471 — intervention group
Group type: COMPARATOR
Intervention: Control (2 ml saline IV)
Number of subjects: 90
Study 35366811 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position (Group L)
Number of subjects: 40
Study 35366811 — intervention group
Group type: COMPARATOR
Intervention: Supine position (Group S)
Number of subjects: 40
Study 35366811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 33581481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 33581481 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 0
Study 33581481 — intervention group
Group type: COMPARATOR
Intervention: Weekly sessions
Number of subjects: 0
Study 33581481 — intervention group
Group type: COMPARATOR
Intervention: Twice weekly sessions
Number of subjects: 0
Study 32556293 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID‐19 prognostic signature based on neutrophil count, lymphocyte count, procalcitonin, age, and C‐reactive protein
Number of subjects: 0
Study 32556293 — intervention group
Group type: COMPARATOR
Intervention: COVID‐19 prognostic signature
Number of subjects: 0
Study 35428889 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 mcg daily)
Number of subjects: 41
Study 35428889 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months)
Number of subjects: 41
Study 35428889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with teriparatide followed by denosumab
Number of subjects: 41
Study 33753685 — intervention group
Group type: EXPERIMENTAL
Intervention: Dangerous practices observed among barbers
Number of subjects: 138
Study 33753685 — intervention group
Group type: EXPERIMENTAL
Intervention: Better attitude regarding BBVI
Number of subjects: 138
Study 33753685 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased years of schooling
Number of subjects: 138
Study 32732022 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet
Number of subjects: 988
Study 32732022 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 988
Study 36229342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ChAdOx1 nCoV-19 (5 × 10^9 VP, n=6)
Number of subjects: 30
Study 36229342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ChAdOx1 nCoV-19 (2 × 10^10 VP, n=12)
Number of subjects: 30
Study 36229342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ChAdOx1 nCoV-19 (5 × 10^10 VP, n=12)
Number of subjects: 30
Study 36229342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ChAdOx1 nCoV-19 (5 × 10^10 VP) as a booster
Number of subjects: 30
Study 36229342 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular mRNA SARS-CoV-2 vaccination
Number of subjects: 30
Study 36229342 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ChAdOx1 nCoV-19
Number of subjects: 30
Study 36229342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ChAdOx1 nCoV-19
Number of subjects: 30
Study 33406103 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilderness programs employing adventure therapy
Number of subjects: 15
Study 34983195 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1298
Study 34983195 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1298
Study 34983195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension in women
Number of subjects: 1298
Study 34983195 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia in men
Number of subjects: 1298
Study 33273048 — intervention group
Group type: EXPERIMENTAL
Intervention: UBICARE technology
Number of subjects: 0
Study 32948350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar absorption test on days 4, 7, and 14 postpartum
Number of subjects: 12
Study 34491219 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching parents about dengue using a booklet
Number of subjects: 142
Study 34491219 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching parents about dengue without a booklet
Number of subjects: 142
Study 34491219 — intervention group
Group type: COMPARATOR
Intervention: Learning from an expert
Number of subjects: 142
Study 34491219 — intervention group
Group type: COMPARATOR
Intervention: Learning about an unrelated topic
Number of subjects: 142
Study 32440004 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP (post-activation potentiation) warm-up consisting of 2×5 arm-pulls with resistance bands
Number of subjects: 12
Study 32440004 — intervention group
Group type: COMPARATOR
Intervention: Non-PAP (control condition) warm-up
Number of subjects: 12
Study 35013427 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment control (individuals who can stop ART without viral load rebound)
Number of subjects: 14
Study 35013427 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Score based on expression of four genes (ISG15, XAF1, TRIM25, USP18)
Number of subjects: 14
Study 33725860 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic repair of bursal‐sided partial-thickness rotator cuff tears
Number of subjects: 0
Study 33725860 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic repair of articular‐sided partial-thickness rotator cuff tears
Number of subjects: 0
Study 32631243 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Stress Questionnaire (WSQ) intervention with physicians' feedback
Number of subjects: 271
Study 32631243 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 271
Study 35487712 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 0
Study 35487712 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 0
Study 33847426 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety/Signs of Safety model
Number of subjects: 500000
Study 34506719 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter therapy (LT) twice a week for 2 weeks
Number of subjects: 41
Study 34506719 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (no treatment during the same period)
Number of subjects: 41
Study 32083766 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (50.4 Gy in supraclavicular field and 56 Gy in mediastinal field in 28 fractions over 6 weeks)
Number of subjects: 157
Study 32083766 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 157
Study 32083766 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 157
Study 35098613 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (0.25 Hz, 60 stimuli each, 2 sessions)
Number of subjects: 62
Study 35098613 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (0.25 Hz, 60 stimuli each, 2 sessions)
Number of subjects: 62
Study 35098613 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 62
Study 35098613 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 62
Study 33691760 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid ('Kidney Stone Choice')
Number of subjects: 0
Study 33691760 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 35437092 — intervention group
Group type: EXPERIMENTAL
Intervention: JumpMath
Number of subjects: 29
Study 35437092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed
Number of subjects: 29
Study 35437092 — intervention group
Group type: COMPARATOR
Intervention: Active Control/Reading
Number of subjects: 29
Study 33950375 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1452
Study 33950375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1452
Study 33177734 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management exercise intervention
Number of subjects: 70
Study 33177734 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention
Number of subjects: 70
Study 35843545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar salpingectomy
Number of subjects: 51
Study 35843545 — intervention group
Group type: COMPARATOR
Intervention: Traditional salpingectomy
Number of subjects: 51
Study 35843545 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 51
Study 33547015 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) after RYGB
Number of subjects: 20
Study 33547015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (EE) after RYGB
Number of subjects: 20
Study 33547015 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel (LNG) in controls
Number of subjects: 20
Study 33547855 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic acellular dermal matrix (ADM) combined with autologous razor-thin graft
Number of subjects: 64
Study 33547855 — intervention group
Group type: COMPARATOR
Intervention: Autologous scar tissue combined with autologous razor-thin graft
Number of subjects: 64
Study 35869334 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D display technique
Number of subjects: 89
Study 35869334 — intervention group
Group type: COMPARATOR
Intervention: 4K-2D display technique
Number of subjects: 89
Study 33211870 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg SC Q6M (long-term arm)
Number of subjects: 1969
Study 33211870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (crossover arm)
Number of subjects: 1969
Study 35908037 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative strengthening exercise program
Number of subjects: 129
Study 35908037 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 129
Study 33065774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (SOF/VEL) plus ribavirin for 12 weeks
Number of subjects: 0
Study 33065774 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (no DAA therapy)
Number of subjects: 0
Study 33865519 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (ARNI)
Number of subjects: 256
Study 35575618 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation (550 mg/d)
Number of subjects: 30
Study 35575618 — intervention group
Group type: COMPARATOR
Intervention: Control (25 mg/d d9-choline)
Number of subjects: 30
Study 33665769 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF) at day 3
Number of subjects: 44
Study 33665769 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF) at day 5
Number of subjects: 44
Study 33665769 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF) at hospital discharge
Number of subjects: 44
Study 33665769 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor (VEGF) at day 1
Number of subjects: 44
Study 33665769 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor (VEGF) at hospital discharge
Number of subjects: 44
Study 33665769 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures of BDNF
Number of subjects: 44
Study 33665769 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures of VEGF
Number of subjects: 44
Study 33665769 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuron specific enolase (NSE) at day 0
Number of subjects: 44
Study 32772684 — intervention group
Group type: EXPERIMENTAL
Intervention: DTAS
Number of subjects: 60
Study 32772684 — intervention group
Group type: COMPARATOR
Intervention: CTT
Number of subjects: 60
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Number of subjects: 2614
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor
Number of subjects: 2614
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine
Number of subjects: 2614
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 2614
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 2614
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Number of subjects: 2614
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 2614
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 2614
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 2614
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C
Number of subjects: 2614
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 2614
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline CD4 count
Number of subjects: 2614
Study 33409691 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 70
Study 33409691 — intervention group
Group type: EXPERIMENTAL
Intervention: 70S30C‐BAG
Number of subjects: 70
Study 32484629 — intervention group
Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion
Number of subjects: 418
Study 32484629 — intervention group
Group type: COMPARATOR
Intervention: vehicle lotion
Number of subjects: 418
Study 33890535 — intervention group
Group type: EXPERIMENTAL
Intervention: Bangerter filters (BF) strength 0.1
Number of subjects: 23
Study 33890535 — intervention group
Group type: EXPERIMENTAL
Intervention: Bangerter filters (BF) strength 0.2
Number of subjects: 23
Study 33890535 — intervention group
Group type: EXPERIMENTAL
Intervention: Bangerter filters (BF) strength 0.4
Number of subjects: 23
Study 33890535 — intervention group
Group type: EXPERIMENTAL
Intervention: Bangerter filters (BF) strength 0.6
Number of subjects: 23
Study 33890535 — intervention group
Group type: EXPERIMENTAL
Intervention: Bangerter filters (BF) (all strengths)
Number of subjects: 23
Study 32519957 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% polidocanol
Number of subjects: 150
Study 32519957 — intervention group
Group type: COMPARATOR
Intervention: 5% phenol
Number of subjects: 150
Study 35346103 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive radical hysterectomy using an endoscopic stapler
Number of subjects: 124
Study 35346103 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy
Number of subjects: 124
Study 32959909 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 80
Study 32959909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32990609 — intervention group
Group type: EXPERIMENTAL
Intervention: Eel biscuits
Number of subjects: 40
Study 32990609 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital snacks
Number of subjects: 40
Study 32869680 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin 0.05% cream
Number of subjects: 25
Study 32869680 — intervention group
Group type: COMPARATOR
Intervention: Moisturizer
Number of subjects: 25
Study 36006951 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery (GraMI) protocol
Number of subjects: 0
Study 36006951 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 615918191 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ)
Number of subjects: 89
Study 615918191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 35350983 — intervention group
Group type: EXPERIMENTAL
Intervention: ESP block with 2 mg/kg levobupivacaine
Number of subjects: 35
Study 35350983 — intervention group
Group type: COMPARATOR
Intervention: ESP block with 2 mg/kg levobupivacaine and 5 μg/mL epinephrine
Number of subjects: 35
Study 35350983 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (L and LE)
Number of subjects: 35
Study 33358456 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nerve blocks (NER group)
Number of subjects: 102
Study 33358456 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON group)
Number of subjects: 102
Study 34736429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomotherapy (TT)
Number of subjects: 123
Study 34736429 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CR)
Number of subjects: 123
Study 33081774 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-player VR (MP) group
Number of subjects: 18
Study 33081774 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-player VR (SP) group
Number of subjects: 18
Study 33081774 — intervention group
Group type: COMPARATOR
Intervention: Textbook reading control group (CG)
Number of subjects: 18
Study 32876710 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic osteochondroplasty
Number of subjects: 214
Study 32876710 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic lavage
Number of subjects: 214
Study 32876710 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 214
Study 35249825 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40
Study 35249825 — intervention group
Group type: COMPARATOR
Intervention: SHAM (placebo)
Number of subjects: 40
Study 34921133 — intervention group
Group type: EXPERIMENTAL
Intervention: High erythropoietin (Epo) treatment in wild‐type mice and human volunteers
Number of subjects: 0
Study 34921133 — intervention group
Group type: EXPERIMENTAL
Intervention: EpoR signaling
Number of subjects: 0
Study 36093566 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg selenium as selenium-enriched yeast
Number of subjects: 481
Study 36093566 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg selenium as selenium-enriched yeast
Number of subjects: 481
Study 36093566 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 μg selenium as selenium-enriched yeast
Number of subjects: 481
Study 36093566 — intervention group
Group type: EXPERIMENTAL
Intervention: 100, 200, or 300 μg selenium as selenium-enriched yeast
Number of subjects: 481
Study 36093566 — intervention group
Group type: COMPARATOR
Intervention: Placebo-yeast
Number of subjects: 481
Study 32374188 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced high-protein diet (CRHP)
Number of subjects: 30
Study 32374188 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes diet (CD)
Number of subjects: 30
Study 35280833 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg daily for 5 days)
Number of subjects: 66
Study 35280833 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 66
Study 33070129 — intervention group
Group type: EXPERIMENTAL
Intervention: High-variability practice (multiple words)
Number of subjects: 8
Study 33070129 — intervention group
Group type: COMPARATOR
Intervention: Low-variability practice (single word)
Number of subjects: 8
Study 34230624 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed predictive equation for FFM: FFM = 16.284 + 0.442 × (Height2/Resistance) − 0.13 × age + 0.302 × Weight − 0.121 × Waist Circumference; r2 = 0.86; SEE = 2.32 kg
Number of subjects: 222
Study 34230624 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed predictive equation for LSTM: LSTM = 14.732 + 0.427 × (Height2/Resistance) − 0.125 × age + 0.291 × Weight − 0.115 × Waist Circumference; r2 = 0.92; SEE = 2.29 kg
Number of subjects: 222
Study 33874683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration on top of standard therapy (diuretics, cardiotonic, vasodilator) with furosemide (40 mg) given immediately and 24 hours after ultrafiltration.
Number of subjects: 146
Study 33874683 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment plan (diuretics, cardiotonic, vasodilator) without ultrafiltration.
Number of subjects: 146